Isabelle Delrieu, PhD, MPH

 

Leader – Sciences and Technologies for Health

President

Co-founder and Associate

 

Isabelle is a scientist specializing in the fight against infectious diseases in low- and middle-income countries. Initially a researcher in molecular biology in the field of malaria, she has gradually turned to international public health. She has worked for more than 10 years as an epidemiologist and biologist, and since 2017 has been leading the Sciences and Technologies for Health activities at EpiLinks.

In particular, she has developed decision-making tools on the dengue vaccine and participates in expert discussions on the implementation of the pre-vaccination screening strategy in Latin America and the Asia Pacific. She recently coordinated EpiLinks support for response activities to the Covid-19 epidemic in Cameroon.

More generally, her experience includes data and situation analysis and the development of tools, recommendations and adapted strategies. In particular, she helped develop training and communication tools for vaccines against malaria and dengue, and for a new uterotonic for low- and middle-income countries. She carried out an evaluation of a meningitis E-surveillance system in Burkina Faso, and participated in the implementation and analysis of epidemiological field studies of bacterial meningitis in sub-Saharan Africa. She has contributed to the development of epidemiological pharmacovigilance study protocols for the malaria vaccine RTS, S. She has conducted literature reviews on cholera and rotavirus in Africa, as well as capacity building surveys for managers of national malaria control programs in Africa. She is the author of numerous technical reports and scientific publications.

Isabelle has the experience of broad partnerships by working with all actors in public health: ministries of health, pharmaceutical industries, international organizations, foundations, and research institutes.

Isabelle holds a doctorate in molecular and cellular biology from Paul Sabatier University in Toulouse and a master’s degree in public health from the Pasteur-Cnam School of Public Health in Paris.

As co-founder and president, Isabelle is responsible for the scientific and external communication of EpiLinks and contributes to the strategic, organizational and administrative activities of the company.

Publications

Updated recommendations of the International Dengue Initiative expert group for CYD-TDV vaccine implementation in Latin America

Torres JR, Falleiros-Arlant LH, Gessner BD, Delrieu I, Avila-Aguero ML, Giambernardino HIG, Mascareñas A, Brea J, Torres CN, Castellanos-Martinez JM.

Updated recommendations of the International Dengue Initiative expert group for CYD-TDV vaccine implementation in Latin America. Vaccine. 2019 Oct 8;37(43):6291-6298. doi: 10.1016/j.vaccine.2019.09.010. Epub 2019 Sep 9.PMID: 31515144

Link to the publication

Natural immunity against capsular group X N. meningitidis following an outbreak in Togo, 2007. 2018

Norheim G, Mueller JE, Njanpop-Lafourcade BM, Delrieu I, Findlow H, Borrow R, Xie O, Nagaputra J, Ramasamy R, Dold C, Tamekloe TA, Rollier CS, Watt H, Kere AB, Næss LM, Pollard AJ.

Natural immunity against capsular group X N. meningitidis following an outbreak in Togo, 2007. Vaccine. 2018 Feb 28;36(10):1297-1303. doi: 10.1016/j.vaccine.2018.01.031. Epub 2018 Feb 2. PubMed PMID: 29397226.

From current vaccine recommendations to everyday practices: An analysis in five sub-Saharan African countries. 2015

Delrieu I, Gessner BD, Baril L, Roset Bahmanyar E.

From current vaccine recommendations to everyday practices: An analysis in five sub-Saharan African countries. Vaccine. 2015 Dec 16;33(51):7290-7298. doi: 10.1016/j.vaccine.2015.10.107. Epub 2015 Nov 3. PubMed PMID: 26546260.

Malaria Transmission Blocking Vaccine Technical Consultation Group. Design of a Phase III cluster randomized trial to assess the efficacy and safety of a malaria transmission blocking vaccine. 2015

Delrieu I, Leboulleux D, Ivinson K, Gessner BD;

Malaria Transmission Blocking Vaccine Technical Consultation Group. Design of a Phase III cluster randomized trial to assess the efficacy and safety of a malaria transmission blocking vaccine. Vaccine. 2015 Mar 24;33(13):1518-26. doi: 10.1016/j.vaccine.2015.01.050. Epub 2015 Feb 10. Review. PubMed PMID: 25681064.

Cholera outbreaks in Africa. Curr Top Microbiol Immunol. 2014

Mengel MA, Delrieu I, Heyerdahl L, Gessner BD.

Cholera outbreaks in Africa. Curr Top Microbiol Immunol. 2014;379:117-44. doi: 10.1007/82_2014_369. PubMed PMID: 24827501.

Characterization of size, structure and purity of serogroup X Neisseria meningitidis polysaccharide, and development of an assay for quantification of human antibodies. 2012

Xie O, Bolgiano B, Gao F, Lockyer K, Swann C, Jones C, Delrieu I, Njanpop-Lafourcade BM, Tamekloe TA, Pollard AJ, Norheim G.

Characterization of size, structure and purity of serogroup X Neisseria meningitidis polysaccharide, and development of an assay for quantification of human antibodies. Vaccine. 2012 Aug 31;30(40):5812-23. doi: 10.1016/j.vaccine.2012.07.032. Epub 2012 Jul 24. PubMed PMID: 22835740.

Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso. 2011

Delrieu I, Yaro S, Tamekloé TA, Njanpop-Lafourcade BM, Tall H, Jaillard P, Ouedraogo MS, Badziklou K, Sanou O, Drabo A, Gessner BD, Kambou JL, Mueller JE.

Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso. PLoS One. 2011;6(5):e19513. doi: 10.1371/journal.pone.0019513. Epub 2011 May 20. PubMed PMID: 21625480; PubMed Central PMCID: PMC3098835.

Functional characterization of an LCCL-lectin domain containing protein family in Plasmodium berghei. J Parasitol. 2004

Trueman HE, Raine JD, Florens L, Dessens JT, Mendoza J, Johnson J, Waller CC, Delrieu I, Holders AA, Langhorne J, Carucci DJ, Yates JR 3rd, Sinden RE.

Functional characterization of an LCCL-lectin domain containing protein family in Plasmodium berghei. J Parasitol. 2004 Oct;90(5):1062-71. PubMed PMID: 15562607.

Insulin and estrogen receptor ligand influence the FGF-2 activities in MCF-7 breast cancer cells. Biochem Pharmacol. 2003

Garnier M, Giamarchi C, Delrieu I, Rio MC, Chinestra P, Bayard F, Poirot M, Faye JC.

Insulin and estrogen receptor ligand influence the FGF-2 activities in MCF-7 breast cancer cells. Biochem Pharmacol. 2003 Feb 15;65(4):629-36. PubMed PMID: 12566092.

PSLAP, a protein with multiple adhesive motifs, is expressed in Plasmodium falciparum gametocytes. Mol Biochem Parasitol. 2002

Delrieu I, Waller CC, Mota MM, Grainger M, Langhorne J, Holder AA.

PSLAP, a protein with multiple adhesive motifs, is expressed in Plasmodium falciparum gametocytes. Mol Biochem Parasitol. 2002 Apr 30;121(1):11-20. PubMed PMID: 11985859.

IL-6 promoter is modulated by the 24 kDa FGF-2 isoform fused to the hormone binding domain of the oestrogen receptor. 2000

Delrieu I, Chinestra P, Delassus F, Bayard F, Prats H, Faye JC. IL-6 promoter is modulated by the 24 kDa FGF-2 isoform fused to the hormone binding domain of the oestrogen receptor. Cytokine. 2000 Jul;12(7):1110-4. PubMed PMID: 10880259.

The high molecular weight isoforms of basic fibroblast growth factor (FGF-2): an insight into an intracrine mechanism. 2000

Delrieu I.

The high molecular weight isoforms of basic fibroblast growth factor (FGF-2): an insight into an intracrine mechanism. FEBS Lett. 2000 Feb 18;468(1):6-10. Review. PubMed PMID: 10683430.

Expression of the interleukin-6 gene is constitutive and not regulated by estrogen in rat vascular smooth muscle cells in culture. 1999

Maret A, Clamens S, Delrieu I, Elhage R, Arnal JF, Bayard F.

Expression of the interleukin-6 gene is constitutive and not regulated by estrogen in rat vascular smooth muscle cells in culture. Endocrinology. 1999 Jun;140(6):2876-82. PubMed PMID: 10342880.

Inhibition of interleukin-6 promoter activity by the 24 kDa isoform of fibroblast growth factor-2 in HeLa cells. 1999

Delrieu I, Faye JC, Bayard F, Maret A.

Inhibition of interleukin-6 promoter activity by the 24 kDa isoform of fibroblast growth factor-2 in HeLa cells. Biochem J. 1999 May 15;340 ( Pt 1):201-6. PubMed PMID: 10229675; PubMed Central PMCID: PMC1220238.

Overexpression of the FGF-2 24-kDa isoform up-regulates IL-6 transcription in NIH-3T3 cells. 1998

Delrieu I, Arnaud E, Ferjoux G, Bayard F, Faye JC.

Overexpression of the FGF-2 24-kDa isoform up-regulates IL-6 transcription in NIH-3T3 cells. FEBS Lett. 1998 Sep 25;436(1):17-22. PubMed PMID: 9771886.